Funding for 3CTN member centres to has led to remarkable improvements in trial participation & conduct. Thank you, funders, members, and patients for your ongoing support.

#CCTG would like to extend our congratulations to @bertagnollimm on her upcoming appointment as new director of the National Cancer Institute. Your Canadian partners in clinical trial research are looking forward to working with you! whitehouse.gov/briefing-room/… via The White House

#CCTG2023 Annual Spring Meeting of Participants is coming soon! We are in person this year so don't forget to save the dates April 28 – April 30.

Today #ASCO23 Dr Marie Plante will present #CCTG CX5/SHAPE study results that show simple hysterectomy is a safe option for women with early-stage, low-risk cervical cancer. ctg.queensu.ca/cctg_media_rel… CIHR Canadian Cancer Society #GCIG @Asco CHU de Québec-Université Laval Arcagy-Gineco The Netherlands Cancer Institute

#ResearchBreakthrough – CCTG congratulations to Dr Plante, SHAPE partner investigators and patients for completing a study that changes standards across the globe. Simple hysterectomy is safe for women with early-stage, low-risk cervical cancer. Less is more.

Congratulations Dr Peter Ellis et al presenting TIP Poster of I238 testing safety and efficacy of IO rechallenge at progression in patients with prior serious irAE but excellent response

Learning about the microbiome and value of FMT from @ArielleElkrief formerly Memorial Sloan Kettering Cancer Center and now new faculty, UDMontreal. Looking forward to working with you CCTG

“The data presented today demonstrate that the use of pembrolizumab and platinum-pemetrexed chemotherapy extends the lives of patients with unresectable advanced or metastatic pleural mesothelioma,” said Dr Quincy Chu, #CCTG study chair for IND227 #solvingcancertogether

Another shout out to CCTG participating in 2/4 plenary #ASCO2023 demonstrating pfs and efs advantage with Nivolumab vs Brentuximab +AVD. Notably decreasing the need for EOT radiation especially in peds patients! Excellent collaborative study in adults/ped.

Today at #ASCO23 CCTG IND240 (CRI-CCTG-0003) poster for an immunotherapy platform study in platinum-resistant high grade serous ovarian cancer (IPROC) Cancer Research Institute IND Program CCTG Poster Session TPS5617: meetings.asco.org/abstracts-pres…

Congratulations, Joe! IMHO you are one of the most important individuals in Canadian cancer research, past or present. Your efforts led to new standards of care for patients & the high international regard, productivity and connectiveness of the CDN cancer research community.

We carefully assessed timing & features of ctDNA response and correlated with clinical outcomes in the first stage of BR36 published today in Nat Medicine. We use these results in Stage II to evaluate ctDNA to tailor treatment to improve survival of NSCLC patients.

Terrific selection! Congratulations,Lillian!

Honour and privilege to work with this team, with patients, and with support of Weston Family Foundation , Canadian Cancer Society well as CIHR on this trial which aims to improve outcomes for patients with melanoma. Thank you!

The Canadian Cancer Trials Group (#CCTG) is joining forces with Marathon of Hope Cancer Centres Network (#MOHCCN) to conduct three pan-Canadian projects with the goal of increasing the effectiveness of #immunotherapy for cancer patients. #CancerResearch #ClinicalTrials bit.ly/4cvVlPb

As inaugural ICR SD & CCRA cofounder, Phil Branton championed collaborative research including that of CCTG and cancer trials. Saddened by his loss and grateful for his lasting impact on the CDN cancer research community. ccra-acrc.ca/dr-philip-bran… CCTG The Canadian Cancer Clinical Trials Network (3CTN)

This guidance is an important acknowledgement of the value of pragmatic RCTs to inform policy & practice. Academic coop trial groups have long done these RCTs to benefit patients, clinicians, payers, & regulators. Like us trialists, FDA is interested in seeing more of them.

The #CCTG MA40 FINER clinical trial presented at #ASCO25 shows promise in slowing advanced breast cancer progression buff.ly/jm31zwm Roche Breast Cancer Trials

Presented at #ASCO25: A 3-year structured exercise program after adjuvant chemotherapy for colon cancer improved disease-free and overall survival, physical functioning, and fitness, as compared with health education alone. Full CHALLENGE phase 3 trial results:

#ASCO25 ASCO NEJM ✅ Exercise Saves Lives After Colon Cancer ➡️ come watch Dr Chris Booth present the results of the ph3 CO.21 CHALLENGE study - don’t walk, run! 🏃🏃🏻‍♂️🏃 Hall B1 430-6pm 🙏 to our patients, my GI group CCTG 🇨🇦 and our partner GI Cancer Institute and AGITG 🇦🇺🇳🇿for